[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …
…, P Reddy, S Verma, C Singh, SV Redkar… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
[HTML][HTML] Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)
One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …
[HTML][HTML] Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of …
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double-…
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double-…
Immunogenicity and tolerability of BBV154 (iNCOVACC®), an intranasal SARS-CoV-2 vaccine, compared with intramuscular Covaxin® in healthy adults: a …
Background: Unlike intramuscular vaccines, intranasal COVID-19 vaccines may generate
mucosal immunity, which may be critical for to prevent infection and human-to-human …
mucosal immunity, which may be critical for to prevent infection and human-to-human …
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …
Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: A phase 1, double-blind, randomised control trial
Background: BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a Toll-Like Receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or 6 μg …
formulated with a Toll-Like Receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or 6 μg …
A11591 Ambulatory Blood Pressure Monitoring (ABPM) and Holter Monitoring Simultaneously as a Standard Care Approach to Evaluate the Risk Correlates in …
V Redkar, S Redkar, S Redkar, A Inamdar… - Journal of …, 2018 - journals.lww.com
Objectives: We evaluated 3230 (Males= 2228, Females= 1002) hypertensives, hospitalised
for 24 hours to analyse association of hypertension and arrhythmia simultaneously for three …
for 24 hours to analyse association of hypertension and arrhythmia simultaneously for three …